TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.31 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.26 -0.05 (-2.16%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for TFF Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 17 | 34 | 35 | 28 |
Receivables | 0 | 0 | 3 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 1 |
Total Current Assets | 8 | 19 | 39 | 38 | 29 |
Net Property & Equipment | 2 | 3 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2 | 2 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 12 | 24 | 41 | 39 | 29 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 1 | 2 | 1 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 1 | 2 | 1 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 128 | 120 | 104 | 72 | 43 |
Retained Earnings | -118 | -97 | -65 | -34 | -16 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 23 | 39 | 37 | 28 |
Total Liabilities & Shareholder's Equity | 12 | 24 | 41 | 39 | 29 |
Total Common Equity | 10 | 23 | 39 | 37 | 28 |
Shares Outstanding | 2.30 | 1.30 | 1.00 | 0.80 | 0.70 |
Book Value Per Share | 4.16 | 17.60 | 38.74 | 46.68 | 39.49 |
Fiscal Year End for TFF Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 3 | 5 | 10 | 8 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 1 |
Total Current Assets | 6 | 5 | 8 | 11 | 9 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 2 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 2 | 2 | 2 | 2 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 10 | 9 | 12 | 15 | 14 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 1 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 2 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 4 | 2 | 1 | 1 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 135 | 130 | 128 | 127 | 122 |
Retained Earnings | -129 | -124 | -118 | -114 | -109 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 6 | 5 | 10 | 14 | 12 |
Total Liabilities & Shareholder's Equity | 10 | 9 | 12 | 15 | 14 |
Total Common Equity | 6 | 5 | 10 | 14 | 12 |
Shares Outstanding | 3.10 | 2.50 | 2.30 | 2.30 | 1.30 |
Book Value Per Share | 1.90 | 2.12 | 4.16 | 5.95 | 9.45 |